Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
🤖 D.R.A.F.T. Summary
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G
This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is pleased to announce that Canada’s Drug Agency (CDA) has issued a positive reimbursement recommendation with conditions for PrEMPAVELI® (pegcetacoplan) for the treatment of adult […]
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →